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Abstract
Background: Signal Transducer and Activator of Transcription 5 A and B (STAT5) are key survival
factors in cells of the lymphoid lineage. Identification of novel, tissue-specific STAT5 regulated
genes would advance the ability to combat diseases due to aberrant STAT5 signaling. In the present
work a library of human STAT5 bound genomic elements was created and validated.
Results: Of several STAT5 responsive genomic regulatory elements identified, one was located
within the first intron of the human BCL10 gene. Chromatin immuno-precipitation reactions
confirmed constitutive in vivo STAT5 binding to this intronic fragment in various human lymphoid
tumor cell lines. Interestingly, non-phosphorylated STAT5 was found in the nuclei of Kit225 and
YT cells in the absence of cytokine stimulation that paralleled constitutive NFκB activation.
Inhibition of the hyperactive JAK3/STAT5 pathway in MT-2 cells via the Mannich-base, NC1153,
diminished the constitutive in vivo occupancy of BCL10-SBR by STAT5, reduced NFκB activity and
BCL10 protein expression in a dose dependent manner. Moreover, depletion of STAT5 via
selective antisense oligonucleotide treatment similarly resulted in decreased BCL10 mRNA and
protein expression, cellular viability and impaired NFκB activity independent of IL-2.
Conclusion: These results suggest that the NFκB regulator BCL10 is an IL-2-independent STAT5
target gene. These findings proffer a model in which un-activated STAT5 can regulate pathways
critical for lymphoid cell survival and inhibitors that disrupt STAT5 function independent of
tyrosine phosphorylation may be therapeutically effective in treating certain leukemias/lymphomas.

Background
The family of mammalian Signal Transducer and Activator of Transcription (STAT) molecules is composed of 7
members (STAT1–4, 5A, 5B and 6) which mediates a variety of cellular processes including proliferation, differentiation and survival (reviewed in [1]). Current dogma

suggests that STATs are latent factors residing in the
cytosol that only become activated following ligand binding to receptors that initially results in the recruitment and
activation of Janus tyrosine kinases (JAKs). JAKs then
phosphorylate tyrosine residues on the receptor that serve
as docking sites for SH2 domain-containing STATs and
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other signaling molecules. STATs subsequently become
tyrosine phosphorylated by JAKs or other tyrosine kinases,
disengage from the receptor, form dimers via phosphotyrosine-SH2 domain interactions, and translocate to the
nucleus to initiate gene transcription [2,3].
Mammalian STATs can be classified based in parts on
their function in promoting various cellular processes. For
example, STATs 2, 4 and 6 are critical for the immune system to promote viral defense and Th1 versus Th2 differentiation, respectively. Conversely, STATs 1, 3, 5A and 5B are
generally utilized by cytokines and growth factors that
promote cellular growth, proliferation or death (reviewed
in [1]). The members of this second group are associated
with cancer formation, including STAT1 [4]. Intriguingly,
STAT3 and STAT5 promote cell survival through shared
target genes, including Bcl-x and Pim-1 [5-7]. Mice devoid
of Stat5a and Stat5b genes have further established these
proteins as important regulators of T-cell function [8,9].
Interestingly, IL-2 induced T cell proliferation was markedly affected only when both Stat5a and Stat5b genes were
inactivated suggesting that they play redundant roles [9].
In addition to lymphocytes, STAT5A and STAT5B act as
major survival factors for several cell types including
mammary epithelium [10,11] and human prostate cancers [12]. Cancer cells from certain lymphomas and leukemias also display hyper tyrosine-phosphorylated STAT5
as a result of chromosomal translocations, deregulated
tyrosine kinases or viral transformation as reviewed in [1].
Chromatin immuno-precipitation has been a widely utilized method to study direct transcription factor-DNA
interactions [13] and for identifying transcription factor
binding sites in unknown target genes by cloning captured DNA material [14] generated from a genome-wide
library that ultimately can be sequenced and located.
Alternatively, captured DNA material can be hybridized to
microarrays representing (i) CpG rich regions of a genome
that are contained in a significant portion of promoter elements [15] or (ii) non-coding regions within whole chromosomes [16]. Both of these aforementioned methods
have shed new light onto the biological function, location
and kinetics of transcription factor/DNA binding dependent gene expression.
The present study was designed to identify genome-wide
immune specific STAT5 regulated genes. This approach
has shown promise in identifying STAT5 target genes in
mouse pro-B cells [17] and human prolactin treated T47D breast cancer cells [18]. A library of STAT5-bound
genomic fragments was created by cloning and sequencing chromatin immuno-precipitated DNA fragments from
the human lymphoma cell line, YT. One of these
sequences was identified within an intronic element of
the BCL10 gene. We showed that STAT5 constitutively

http://www.molecular-cancer.com/content/8/1/67

occupied this region in vivo in multiple human lymphoid
cell lines. Intriguingly, non-phosphorylated STAT5 was
present in the nuclei of lymphoid cells that paralleled constitutively active NFκB. Disrupting JAK3 activity diminished the in vivo binding of STAT5 to BCL10-SBR in MT-2
cells, reduced NFκB activity and BCL10 protein expression. Furthermore, specific STAT5 depletion correlated
with decreased NFκB DNA-binding, cell viability and
BCL10 protein expression in both the presence and
absence of IL-2. Taken together, these findings indicate a
novel cross-talk mechanism between the STAT5 and NFκB
pathways.

Results and Discussion
Generation of a library encoding STAT5 Binding Regions
Since STAT5 is critical for maintaining lymphoid cell survival [1], we sought to identify putative target genes that
could be responsible for this phenotype. In the present
work a lymphoma-specific library of IL-2-induced STAT5
bound genomic elements was generated by cloning chromatin immuno-precipitated genomic sites directly occupied by STAT5 as described in Figure 1A and in the
Methods.
Validation of STAT5 chromatin immuno-precipitation in
YT cells
In order to confirm that STAT5 was successfully immunoprecipitated from formaldehyde-treated chromatin, YT
cells were stimulated with medium (-) or IL-2 (+) for 30
min at 37°C then fixed with formaldehyde. Next, STAT5
was immuno-precipitated with antibodies raised against
the N-terminus (recognizes both STAT5A and STAT5B,
lanes c-d) or the C-terminus of either STAT5A (lane e) or
STAT5B (lane f), or normal rabbit serum as control IgG
(lane g), separated by SDS-PAGE, and subsequently Western blotted with monoclonal anti-STAT5 antibody. Whole
cell lysate (1% of IP) was also loaded to demonstrate
equal input material for immuno-precipitation (lanes ab). As shown in Figure 1B, all three antibodies were competent to bind STAT5 (indicated by arrow to the right)
from fixed cells as compared to the control (lane g). To
confirm successful capture of genomic elements known to
be occupied by STAT5, qPCR reactions were performed
with primers designed to the region harboring a known
STAT5 binding site within the human IL2RA enhancer
(Positive Regulatory Region PRR III; Figure 1C) [19]. Data
presented in Figure 1C indicated that STAT5 antibody successfully enriched PRR III as compared to control IgG
(nrs).

Next, a library containing STAT5 bound genomic fragments was created by amplification and cloning ChIP-ed
DNA material as described in the Methods. The colonies
were tested for the presence of inserts by direct PCR amplification using vector specific M13 primers (representative
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Figure
(A)
Generation
1
of a library encoding STAT5-responsive genomic elements by ChIP-cloning
(A) Generation of a library encoding STAT5-responsive genomic elements by ChIP-cloning. IL-2 stimulated, formaldehyde cross-linked YT cells were lysed, sonicated and immuno-precipitated with antibodies to STAT5A or STAT5B.
Eluted DNA was ligated to a unidirectional linker (black blocks), amplified and then cloned into pCR II-TOPO vector. Clones
containing inserts were identified by sequencing. (B) Successful immuno-precipitation of STAT5 from formaldehyde
fixed YT cell lysates. YT cells were stimulated with medium (-) or IL-2 (+) then fixed with formaldehyde. Fixed lysates were
immuno-precipitated with antibodies to STAT5 as indicated or normal rabbit serum (IgG CTRL) then Western blotted for
STAT5. Molecular weight markers are indicated to the left side of the panel. Input material corresponds to 1% of cell lysate
used in the immuno-precipitations. (C) Validation of STAT5 ChIP in YT cells. ChIP assay with C-terminal antibodies to
STAT5A and B in combination (αSTAT5 C-term) or IgG control was carried out as described above. The eluted DNA was
then used as template in qPCR reactions with primers designed to PRR III. (D) STAT5 bound genomic library captured
by ChIP-cloning. Inserts were amplified via PCR using M13 primers prior to sequencing and visualized by agarose gel electrophoresis (1%). Stars (*) indicate clones without an insert. (E) Nearby gene mapping of the ChIP-clone identified
genomic sequences. One hundred and nineteen clones were sequenced, 3 fragments were duplicates and 9 were greater
than 300 kb away from any coding region. The remaining sequences that fell within 300 kb from coding regions were analyzed
with Cis-Regulatory Element Annotation System (CEAS). The pie chart represents "%" distribution.
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colonies shown in Figure 1D) prior to sequencing. One
hundred and nineteen clones were sequenced and the
genomic locations analyzed with nearby gene mapping
(CEAS) as described in the Methods. Genomic allocation
of the clones is depicted in Figure 1E demonstrating the
majority of the identified sequences were found in
intronic (38%) and enhancer (51%) regions. These data
are in agreement with earlier findings that binding sites of
transcription factors are not restricted to promoter
regions, rather, a significant portion of these sites are
present in introns [16].
Validation of putative STAT5 binding genomic regions by
EMSA-cold competition assays
To confirm that clones encoding the sequenced genomic
elements (Figure 1D) can be bound by STAT5, inserts
from randomly selected colonies were amplified (from 52
clones, 10 representatives shown in Figure 2A, upper
panel) and used in 30–50-fold molar excess as cold competitors in EMSA assays employing [32P]-labeled probe
corresponding to the STAT5 binding site in the β-casein
gene promoter and nuclear extracts from IL-2 stimulated
YT cells (Figure 2B, lower panel) [14]. The results were
quantitated by comparing the band intensities of the cold
competition EMSA reactions to the control reaction (as
shown in Figure 2A graph). Of 52 validated clones, 24
fragments caused greater than 50% decrease in STAT5
DNA-binding intensity to the radioactively labeled probe.
Table 1 summarizes the genomic location of the 20 validated clones located within 300 kb of coding sequences as
performed by CEAS (four genomic segments were further
than 300 kb from any coding regions).
STAT5 binds an intronic element within the human BCL10
gene in vitro
One putative STAT5 responsive region was identified
within the first intron of the BCL10 gene, a known regulator of NFκB activity and an essential positive regulator of
T and B cell development and activation [20]. The BCL10
gene is located on chromosome 1 and is composed of four
exons and three introns. The STAT5 binding region was
confined to the second intron, proximal to the 5' end of
the third exon which we designated as the BCL10-STAT5
Binding Region (BCL10-SBR). To confirm this finding,
PCR amplified BCL10-SBR was used as a cold competitor
in EMSA assays as described above. Data from two independent experiments (Figure 2B) showed that BCL10-SBR
reduced STAT5 binding to the radioactively labeled probe
greater than 80% suggesting that this element was bound
by STAT5 in vitro. The genomic region surrounding the
STAT5 binding site in the human CISH promoter was also
amplified and used as a positive control. BCL10 is an
adapter molecule implicated in antigen receptor-mediated NFκB signaling by linking to the IκB kinase complex.
The relevance of BCL10 mediated NFκB signaling for lymphoid cells has been described in Bcl10 deficient mice as

Figure
(A)
tition
Validation
EMSA
2 analysis
of the STAT5 genomic library by cold compe(A) Validation of the STAT5 genomic library by cold
competition EMSA analysis. Ten randomly selected
STAT5 bound genomic fragments were amplified with M13
primers (upper panel) and used as cold competitors at 30–
50-fold molar excess in EMSA assays using IL-2 stimulated YT
nuclear extracts and [32P]-labeled STAT5-probe (lower
panel). DNA-binding was expressed as % of control (a reaction without cold competitor (-)) as shown in the graph. The
PCR amplicon surrounding the STAT5 binding site in the
enhancer of the human CISH gene was used as a positive control. (B) Validation of STAT5 binding to BCL10-SBR.
PCR amplified BCL10-SBR was used as a cold competitor in
EMSA assays employing IL-2 stimulated YT nuclear extracts
and [32P]-labeled STAT5-probe (a representative of a BCL10SBR cold competition EMSA analysis is shown). Band intensities were determined by densitometric analysis. The results
presented are an average of two independent experiments
for BCL10-SBR and three for CISH.

T and B cells derived from these animals are nonfunctional and exhibit impaired B/T cell receptor signaling, as
a consequence of impaired NFκB signaling [20,21]. These
results suggest an intriguing cross-talk between the STAT5
and NFκB pathways, which are both implicated in malignant transformation. [1,22]
STAT5 constitutively occupies BCL10-SBR in vivo
Cold competition EMSA assays indicated that BCL10-SBR
can bind STAT5 in vitro. Next, we sought to test whether
STAT5 can also bind this genomic element in vivo. For this
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Table 1: Nearby gene mapping of validated ChIP-cloned sequences.

Chr

Start

End

% DNA-b.

Strand

Dir.

Gene Name

Loc.

1

212539607

212540208

40.79

+
-

U
U

SMYD2
PTPN14

I
E

1

184551050

184551638

46.99

+
+
-

U
D
U

PRG4
C1orf27
TPR

IDS
E
I

1

148762360

148762960

17.71

+
+
-

U
D
U
D

ECM1
ADAMTSL4
C1orf138
APH1A

E
E
E
E

1

85509312

85509912

18.52

+
-

U
U
D

WDR63
BCL10
C1orf52

E
I
E

1

172086277

172086887

3.81

+
+
-

U
D
U
D

DARS2
ZBTB37
SERPINC1
CENPL

I
E
E
E

1

210194877

210195427

35.81

+
-

D
U
D

DTL
INTS7
LPGAT1

E
I
E

2

38751513

38752103

47.52

+
+
-

U
D
U
D

GALM
GEMIN6
SFRS7
HNRPLL

I
E
E
E

3

140069314

140069963

5.83

+
-

U
U
D

FAIM
FOXL2
PIK3CB

E
E
E

4

77775984

77776232

18.02

+
-

U
U
D

SHRM
LOC345079

I
E
E

12

12538539

12539089

13.72

+
+
-

U
D
U
D

LOH12CR1
CREBL2
DUSP16
MANSC1

E
E
I
E

12

22082357

22083007

41.9

+
-

D
U
D

CMAS
ST8SIA1
ABCC9

E
E
E

12

88442012

88442661

26.03

-

U
D

WDR51B
DUSP6

I
E

13

102554697

102555277

9.23

+
-

U
D

ERCC5
SLC10A2

E
E

13

73026115

73026665

34.44

-

U

KLF12

E

14

68177078

68177617

35.78

+
-

U
U

RAD51L1
ZFP36L1

E
E
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Table 1: Nearby gene mapping of validated ChIP-cloned sequences. (Continued)

15

24494535

24495711

32.64

+
-

D
U

GABRA5
GABRB3

E
I

16

73675183

73675822

40.32

+
+
-

U
D
U
D

ZNRF1
ZFP1
LDHD
WDR59

I
E
E
E

16

16389501

16389952

43.06

+
-

U
D

NOMO3
ABCC6

E
E

19

19238022

19238623

13.61

+
+
-

U
D
U
D

CSPG3
KIAA0892
TM6SF2
HAPLN4

E
E
E
E

X

149544804

149545374

27.66

+
+
-

U
D
U

MTM1
MTMR1
CD99L2

I
E
E

Randomly selected sequences (52) were validated by cold competition EMSAs as described in the Methods. Clones (24) with greater than 50%
decrease in STAT5 DNA-binding to the [32P]-labeled probe were analyzed using CEAS. Fragments within 300 kb from coding sequences (20) are
summarized above. (IDS: Immediate Downstream; U: Upstream; D: Downstream; I: Intron; E: Enhancer; chr: chromosome; dir: direction; % DNAb.: % DNA-binding)

analysis, ChIP assays were performed with antibodies to
STAT5 (C-terminal), acetylated-Histone 4 antibody (α
H4-Ac, to confirm active transcription at these sites [23])
or control IgG (normal rabbit serum) in un-stimulated () or IL-2-stimulated (+) Kit225 (Figure 3A), MT2 (Figure
3B) and Hut102 (Figure 3C) cells. Bound DNA was eluted
and amplified with primers specific to PRR III or BCL10SBR via qPCR. Indeed, IL-2-inducible enrichment of PRR
III occurred with the STAT5 C-terminal antibody (lower
panels). Intriguingly, in vivo binding of STAT5 to BCL10SBR was demonstrated in an IL-2-independent manner in
all three cell lines examined (upper panels). These results
demonstrate that STAT5 constitutively occupies BCL10SBR in vivo. However, IL-2-induced enrichment of the
STAT5-responsive PRR III showed that STAT5 was able to
bind DNA in a tyrosine-phosphorylation dependent manner as well in these cell lines. Earlier studies with STAT1
indicated that non-phosphorylated STAT1 had unique
genomic binding sites [24]. Based on these results it may
be logical to assume that non-phosphorylated and phosphorylated (cytokine independent and dependent,
respectively) STAT5 might have unique target sites, different binding characteristics, and perhaps binding partners.
STAT5 is localized to the nucleus of YT and Kit225 cells in
the absence of cytokine stimulation
Current models hold that tyrosine phosphorylated STAT
dimers are required for gene regulation. However, new
evidence suggests that STAT proteins traffic to the nucleus
and regulate gene expression independent of tyrosine
phosphorylation [24-26]. Indeed, data presented in Fig-

ure 3 indicated that STAT5 can bind to BCL10-SBR in a
constitutive manner in three cell types tested in the
absence of IL-2. To confirm this hypothesis, nuclear and
cytosolic proteins were isolated from Kit225 (lanes a-j)
and YT cells (lanes k-t) stimulated with IL-2 for the times
indicated, equal amounts (10 μg) of proteins were separated on 10% SDS-PAGE and Western blotted with PYSTAT5 antibody (specifically recognizes phosphorylated
Y694 and 699 for STAT5A and B, respectively) followed by
re-probing the membrane for total STAT5. Antibodies to
Lamin A/C (nuclear marker) and JAK3 (cytosolic marker)
were employed to confirm the purity of the extraction. As
shown in Figure 4, non-phosphorylated STAT5 was
present in the cell nuclei in the absence of IL-2 stimulation. However, IL-2 was able to induce accumulation of
tyrosine-phosphorylated STAT5 in the nuclear fraction.
These data suggest that the presence of STAT5 in the nuclei
is not dependent on its tyrosine phosphorylation status.
To further demonstrate that non-tyrosine-phosphorylated
STAT5 can localize to the nuclear compartment in lymphoid cells, wild type (wt) or Y694F mutant of mSTAT5A
(unable to undergo tyrosine phosphorylation [27]) were
N-terminally FLAG-tagged and over-expressed in YT cells
as described in the Methods. Next, nuclear extracts were
prepared from cells over-expressing vector alone (Figure
5A, lane a), wt (lanes b-c) or Y694F mSTAT5A (lanes d-e)
stimulated with medium (-) or IL-2 (+) for 30 min at
37°C as indicated. Nuclear extracts were immuno-precipitated with anti-FLAG antibodies then Western blotted
with antibodies to PY (Fig. 5A, upper lane), STAT5 (middle lane) or FLAG (lower lane). While wt mSTAT5A was
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Figure
STAT5 constitutively
3
occupies BCL10-SBR in vivo in Kit225, MT2 and Hut102 cells
STAT5 constitutively occupies BCL10-SBR in vivo in Kit225, MT2 and Hut102 cells. Kit225 cells (A) were made
quiescent in medium without IL-2 for 24 h, MT2 (B) and Hut102 (C) cells were grown until exhaustion. Cells were then stimulated with medium (-) or IL-2 (+) for 30 min at 37°C, then fixed with 1% formaldehyde for 10 min at room temperature and
then chromatin immuno-precipitated with antibodies to Acetyl-Histone 4, C-terminal STAT5 or control IgG. The eluted DNA
was amplified with primers corresponding to PRR III (black bars) or BCL10-SBR (grey bars). Representative data for MT2,
Hut102 (n = 2), and Kit225 cells (n = 3) are shown. Input material represents 5% of immuno-precipitated chromatin.
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Figure 4localized STAT5 is present in YT and Kit225 cells in the absence of IL-2 stimulation
Nuclear
Nuclear localized STAT5 is present in YT and Kit225 cells in the absence of IL-2 stimulation. Equal amounts (10
μg) of nuclear and cytosolic proteins (Kit225: lanes a-j, YT: lanes k-t) were resolved on a 10% SDS-PAGE and Western blots
performed with PY-STAT5, STAT5, Lamin A/C (nuclear marker) or Jak3 (cytosolic marker) antibodies (indicated to the right).
Representative data from three independent experiments are presented.

tyrosine-phosphorylated upon IL-2 stimulation, the
Y694F mutant was not. However, both wt and Y694F
mSTAT5A were constitutively present in the cell nuclei
suggesting that STAT5 nuclear localization can occur in
the absence of tyrosine phosphorylation. To confirm that
YT cells over-expressing Y694F mSTAT5A retained the
ability to respond to IL-2, as well as to demonstrate that
STAT5 nuclear presence was not due to contamination
with cytosolic proteins, whole nuclear extracts isolated
above were Western blotted with PY-STAT5 then re-blotted with antibodies to STAT5, Lamin A/C (a nuclear
marker) followed by β-actin (cytosolic marker) as shown
in Figure 5B. Similar results were obtained with Y699F
mSTAT5B (data not shown).
Traditionally, STAT transcription factors were thought to
reside in the cytoplasm in the absence of cytokine stimulation, and only enter the nucleus to bind DNA and initiate gene expression following cytokine engagement
[2,28]. However, interesting new evidence suggests that
nuclear-localized non-tyrosine-phosphorylated STATs can
regulate gene expression. Indeed, interferon-mediated
gene expression changes in a STAT1-deficient cell line
transfected with a Y699A mutant of STAT1 unable to
become tyrosine-phosphorylated proved it can initiate
constitutive gene expression [24]. Other recent publications have reported that STAT3 can also induce gene transcription in the absence of tyrosine phosphorylation [26].
Moreover, non-phosphorylated, nuclear localized STAT6
in a non-small cell lung cancer model was shown to drive
cyclooxygenase-2 expression independent of its tyrosine
phosphorylation status [25]. Our results provide the first
evidence that non-tyrosine-phosphorylated, nuclearlocalized STAT5 may also play a similar and critical role in
gene regulation in lymphoid cells in the absence of stimulation/activation.

NFκB is constitutively active in YT, Kit225 cells and
activated human PBMCs
Since BCL10 is a positive regulator of NFκB [20], next we
sought to test the activation status of NFκB in lymphoid
cells. EMSA analysis was performed with either a [32P]labeled NFκB (lower panel) or STAT5 (upper panel) probe
and 5 μg nuclear extracts from YT (Figure 6A, lanes b-d),
Kit225 (lanes e-g) cells or naïve (lanes h-j) and activated
(lanes k-m) human PBMCs stimulated with medium (-)
or IL-2 (+) for 30 min. Figure 6A demonstrated that while
IL-2 was able to induce DNA-binding of STAT5 in YT (lane
c), Kit225 (lane f) and PBMCs (lane l), NFκB DNA-binding was constitutive in these cells. Naïve PBMCs, which
did not respond to IL-2, did not display binding to either
probe, thus verifying that constitutive NFκB binding was
not an artifact resulting from nuclear extraction. To confirm the specificity of the observed bands, a reaction without nuclear extract (Free probe) and cold competition
assays with the corresponding unlabeled probes (c.p.)
were also performed (lanes d, g, j and m). To further verify
the specificity of the NFκB bands, antibodies to p50 (Figure 6B, lane c), p65 (lane d) or both (lane e) were used in
supershift analyses. Indeed, both p50 and p65 antibodies
resulted in partial supershifts of the NFκB band, while
using these antibodies in combination resulted in a complete supershift. On the contrary, normal goat serum (IgG
ctrl, lane f) did not result in a supershift of the NFκB
bands.
Blockade of the JAK3/STAT5 pathway diminishes in vivo
STAT5 binding to BCL10-SBR, impairs NFκB function and
reduces BCL10 expression
In order to confirm that the in vivo binding of STAT5 to
BCL10-SBR is responsive to the inhibition of the JAK3/
STAT5 pathway, we employed the selective JAK3 inhibitor
NC1153 [29]. Although the precise regulation of STAT5
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Figure 5
Y694F-mSTAT5A
can localize to the nuclei of YT cells
Y694F-mSTAT5A can localize to the nuclei of YT
cells. (A) YT cells over-expressing vector alone (Vector), wt
or Y694F mSTAT5A were stimulated with medium (-) or IL2 (+) for 30 min at 37°C. Nuclear extracts were prepared
and immuno-precipitated with anti-FLAG antibodies,
resolved on 7.5% SDS-PAGE then Western blotted with PY
antibodies followed by re-blotting with antibodies to STAT5
and FLAG as indicated to the right. (B) Nuclear extracts isolated as described above were resolved on a 7.5% SDSPAGE, Western blotted with PY-STAT5 antibody then reblotted with antibodies to STAT5, Lamin A/C and β-actin as
indicated to the right.

by JAK3 is not yet fully understood, it has been shown that
phosphorylated STAT1 and STAT3 can increase the expression of non-phosphorylated STAT1 and STAT3, respectively [30]. Therefore, it was hypothesized that nonphosphorylated STAT5 function could partially be
affected by the inhibition of phosphorylated STAT5. First,
the activation status of the JAK3/STAT5 pathway was
tested in MT-2 cells treated with ascending amounts of
NC1153 for 24 h as indicated (Figure 7A, lanes c-e) by
Western blotting. Constitutive tyrosine phosphorylation
of STAT5 was diminished by NC1153 in a dose dependent
manner as compared to non-treated (NT, lane a) or vehicle treated (DMSO, lane b) samples. Equal loading was
confirmed by re-probing the membrane with antibodies
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to STAT5 and GAPDH. Moreover, tyrosine phosphorylation of JAK3 was similarly decreased upon NC1153 treatment (data not shown). Next, in vivo binding of STAT5 to
PRR III and BCL10-SBR were assessed by ChIP assays and
qPCR. As presented in Figure 7B, the occupancy of these
regions by STAT5 was reduced in a dose dependent manner upon NC1153 (expressed as fold change of STAT5
binding over background (IgG control)). Lastly, the functional effect of JAK3 blockade on the expression of BCL10
protein and the activation status of NFκB was assessed.
Since BCL10 is a known regulator of NFκB signaling in
lymphoid cells [20] that is a critical pathway for mediating survival of activated B- and T-cells, it was reasonable
to assume that STAT5 depletion mediated decrease of
BCL10 expression might lead to diminished constitutive
NFκB activation. For this assay, MT-2 cells were treated
with DMSO (Figure 7C, lane a) or ascending concentrations of NC1153 for 48 h as indicated (lanes b-d), then
harvested and Western blotted with antibodies to phospho-p65/NFκB, p65/NFκB and BCL10. Indeed, data presented in Figure 7C demonstrated that phosphorylation
of p65 NFκB on Ser536, an indicator of its enhanced transcriptional activity [31], was decreased in parallel to
BCL10 protein expression upon NC1153 treatment. Equal
loading was confirmed by re-probing the membrane with
GAPDH (lower panel). It should be noted that some
reduction in the level of total p65 resulted from the treatments with higher concentrations of NC1153 that could
be due to decreased cellular viability at this time point.
However, the lowest dose of NC1153 (10 μM) did not
affect total p65 but reduced its Ser536 phosphorylation as
well as BCL10 levels confirming that these reductions
were not due to non-specific treatment effects.
STAT5 depletion reduces BCL10 mRNA and protein
expression, decreases the viability of Kit225 leukemia cells
and diminishes NFκB DNA binding independently of IL-2
stimulation
In order to test whether STAT5 has a direct role in regulating BCL10 expression and that this effect is independent
of cytokines, antisense STAT5 ODN targeting both
STAT5A and B were utilized. Earlier results demonstrated
that STAT5 is a critical survival factor for activated T-cells
and some lymphoid cell lines. [32] First, Kit225 cells were
left untreated (Figure 8A and 8B, NT), electroporated
without ODN (EP), with 2.5 or 5 μM antisense STAT5
ODN (AS STAT5) or 2.5 or 5 μM control ODN (CTRL),
cultured in medium without (not shown) or with IL-2 for
24 h, and then harvested. Messenger RNA levels of BCL10
was measured via qRT PCR with primers specific to
human BCL10 (Figure 8A) as described in the Methods.
STAT5 depleted, but not control treated samples, displayed reduced BCL10 transcript levels. Next, parallel
samples were lysed, equal amounts of lysates resolved on
12% SDS-PAGE and Western blotted with antibodies to

Page 9 of 16
(page number not for citation purposes)

Molecular Cancer 2009, 8:67

http://www.molecular-cancer.com/content/8/1/67

Figureis 6constitutively active in multiple lymphoid cells
NFκB
NFκB is constitutively active in multiple lymphoid cells (A) YT (lanes b-d), quiescent Kit225 (lanes e-g), naïve (lanes hj) and quiescent activated human PBMCs (lanes k-m) were stimulated with IL-2 for 30 min before nuclear extracts were prepared. Equivalent amounts (5 μg) were used in EMSA reactions employing a STAT5 (upper panel) or NFκB radio-labeled probe
(lower panel). A reaction without nuclear extract (free probe, lane a) or with unlabeled probes (lanes d, g, j, m) were used to
confirm the specificity of the bands. (B) Constitutive NFκB is composed of p50 and p65 subunits in lymphoid cells.
Antibodies to p50 (lane c) and p65 (lane d) subunits of NFκB were used either alone or in combination (lane e) for supershift
assays in Kit225 nuclear extracts. Control IgG (normal goat serum, lane f) and a reaction without nuclear extract (free probe,
lane a) were used to confirm the specificity of the bands. Star (*) indicates a non-specific band.

BCL10 (Figure 8B). The blot was then re-probed with antibodies to STAT5 and GAPDH (as a loading control).
Decreased STAT5 expression (Figure 8B, upper panel,
lanes c-d) correlated with reduced BCL10 protein levels
(middle panel) in a dose dependent manner, while
GAPDH levels were not affected (lower panel). Kit225
cells depleted of STAT5 and cultured in the absence of IL-

2 also displayed reduced BCL10 protein levels compared
to controls (data not shown). Taken together, these data
further support the notion that STAT5 regulates BCL10
expression.
Since STAT5 promotes lymphoid cell survival [32,33], cell
viability following STAT5 depletion was also assessed by
Page 10 of 16
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JAK3/STAT5
Figure 7
blockade inhibits constitutive STAT5 tyrosine phosphorylation and BCL10/NFκB activity in MT-2 cells
JAK3/STAT5 blockade inhibits constitutive STAT5 tyrosine phosphorylation and BCL10/NFκB activity in MT-2
cells. (A) MT-2 cells were treated with medium, DMSO (0.1%, vehicle control) ascending amounts of NC1153 as indicated for
24 h. Total cell lysates were Western blotted with antibodies as indicated to the right. Molecular weight markers are indicated
to the left. (B) JAK3 blockade diminishes BCL10-SBR occupancy by STAT5 in vivo. MT-2 cells were treated with
NC1153 as indicated for 10 h. ChIP assays were performed with anti-STAT5 antibody and IgG control from each treatment.
STAT5 DNA binding is expressed as fold change over background (IgG control). (C) NC1153 reduces NFκB activity and
BCL10 protein expression. MT-2 cells were treated as described above for 48 h. Total cell lysates were Western blotted
with antibodies indicated to the right. Molecular weight markers are shown to the left.
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Figure
(A)
STAT5
8 depletion decreases BCL10 mRNA expression in a dose dependent manner
(A) STAT5 depletion decreases BCL10 mRNA expression in a dose dependent manner. Kit225 cells were treated
with antisense STAT5 (AS STAT5) or control (CTRL) ODN as indicated and cultured for 24 h. Cells were harvested in duplicates. One pellet was used for total RNA isolation and cDNA preparation as described in the Methods. QRT-PCR was performed with primers specific to human BCL10. (B) STAT5 depletion decreases BCL10 protein expression. Parallel cell
pellets were lysed and equal amounts (10 μg) of lysates resolved on 10% SDS-PAGE, then Western blotted with antibodies to
BCL10, STAT5, followed by re-probing with antibodies to GAPDH (as a loading control). Representative data from two independent experiments are shown. (C) STAT5 depletion decreases Kit225 cell viability. Cell viability following electroporation (24 h) was assessed using MTS assay as described in the Methods. Cells were cultured either in the absence (white bars)
or presence (black bars) of IL-2. Representative data from three independent experiments are shown. (* p < 0.001) (D) Antisense STAT5 treatment decreases NFκB DNA binding. Kit225 cells were electroporated with either AS STAT5 (AS
STAT5) or control ODN (CTRL) and cultured in medium without (-) or with (+) IL-2 for 24 h. Nuclear proteins were isolated
and incubated with [32P]-labeled NFκB probe (indicated to the right). Corresponding un-labeled NFκB probe in 100-fold molar
excess (lane e) or free probe (lane f) was used to confirm the binding specificity. % DNA-binding was calculated by normalizing
band intensities of STAT5 ODN treated samples to the corresponding CTRL ODN treated samples (100%). Representative
data from two independent experiments are shown.
MTS assays. As shown in Figure 8C, reduced STAT5 and
BCL10 expression decreased Kit225 cell viability in a dose
dependent manner, regardless of the absence (white bars)
or presence (black bars) of IL-2 in the culture medium.
These data further suggest that non-cytokine activated
STAT5 dependent gene regulation may be functionally

important in tumor cell lines such as Kit225. Indeed, IL-2
starved Kit225 cells were greater than 90% viable
(assessed by trypan blue exclusion) after 72 h, although
tyrosine phosphorylated STAT5 was abolished within 24
h (data not shown). Interestingly, antisense oligonucleotide depletion of STAT5 resulted in greater than 50%
Page 12 of 16
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reduction in cell viability within 24 h regardless of IL-2
(Figure 8C).
These results support the hypothesis that the cell survival
promoting activities of STAT5 are, at least partially,
cytokine independent and targets such as BCL10 may be
responsible for this phenotype. To support this notice, the
effect of STAT5 depletion on NFκB function was assessed.
(It should be noted that a lower dose of antisense STAT5
ODN (2.5 μM) was employed within the present studies
in order to avoid massive cellular death that follows
STAT5 depletion.) Nuclear proteins were isolated from
STAT5 antisense or CTRL (2.5 μM) ODN treated Kit225
cells at 24 h as described in the Methods and incubated
with [32P]-labeled NFκB probe. The results presented in
Figure 8D showed reduced constitutive DNA binding of
NFκB following STAT5 depletion (lanes a, c) as compared
to control ODN treated samples (lanes b, d). These data
suggest that STAT5 regulates constitutive NFκB signaling
in an IL-2-independent manner in Kit225 cells.
In summary, our results demonstrate that STAT5 mediated BCL10 expression occurs in the absence or presence
of cytokine stimulation and STAT5 tyrosine phosphorylation. Moreover, these data indicate that STAT5 and NFκB
pathways are interconnected and critical for regulating
lymphoid/leukemic cancer cell proliferation/survival
genes. The functional relevance of these findings is that
therapeutic strategies that seek to disrupt cancer disease
progression by blocking STAT tyrosine phosphorylation
status alone may not prove effective and may be tumor or
cell type dependent. Indeed, targeted disruption of tyrosine and non-tyrosine phosphorylated forms of STAT5
may both be required.

Methods
Cell culture and treatment
The human lymphoma cell lines YT [34] and Hut102
[35], the human T-cell line MT-2 [36], and leukemia cell
line Kit225 [37] were maintained in RPMI-1640 medium
containing 10% fetal calf serum, 2 mM L-glutamine and
penicillin-streptomycin (50 IU/ml and 50 μg/ml, respectively). Kit225 media was supplemented with 20 U/ml
human recombinant IL-2 (NCI Preclinical Repository).
Prior to IL-2 stimulation, Kit225 cells were made quiescent for 24 h in their regular medium without IL-2. Cell
stimulations were carried out with 10 nM IL-2. Antisense
oligodeoxynucleotides (ODN) were synthesized by ISIS
Pharmaceuticals, Inc. and used as previously described
[38].
Chromatin Immuno-precipitation
Chromatin immuno-precipitation was performed as previously described. [18] Chromatin was immuno-precipitated with either anti-STAT5A/B antibody (N-terminal, N-
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20, Santa Cruz Biotechnology Inc.); extreme C-terminal
STAT5A and STAT5B mixture [39] or normal rabbit serum
(IgG control) (Santa Cruz Biotechnology Inc.,) for 3 h at
4°C. DNA was recovered using Qiagen PCR Purification
Kit and ultimately eluted with 100 μl 10 mM Tris pH 8.0.
To confirm successful chromatin immuno-precipitation
in Kit225 cells, PCR amplification of a known STAT5
binding element localized 5' to the human IL2RA gene
within the Positive Regulatory Region III [19] (Forward:
5'-ACG TCT AGA AAG AAA GTG GTC-3' Reverse: 5'-CTG
TCC CTG GAT GAA CCT AGT-3') was performed by quantitative real time PCR (40 cycles of 30 s at 94°C, 30 s at
50°C 30 s at 72°C) and 2× SYBR Green Master Mix from
BioRad on a BioRad iQ5 qPCR machine. BCL10-SBR was
amplified via qPCR with Forward: 5'-CCT GCC ATT ACC
TTT GTC ATT AT-3' and Reverse: 5'-GGG AGT GTT CGA
AAA ATG-3' primers. Values of transcripts in unknown
samples were obtained by interpolating Ct (PCR cycles to
threshold) values on a standard curve. Standard curves
were prepared from known amounts of purified, PCRamplified DNA.
Cloning of STAT5 DNA binding regions
The chromatin immuno-precipitated DNA was blunt
ended by T4 DNA Polymerase (NEB, according to the
manufacturer's recommendations) for 5 min at 37°C and
recovered by purification with Qiagen's PCR Purification
Kit. A unidirectional linker was annealed and ligated to
the blunted DNA pool with T4 DNA ligase (Promega) as
described earlier [40]. DNA was amplified using the linker
as a primer to generate a sufficient amount to clone into
the pCR II-TOPO vector using TOPO TA Cloning Kit with
One Shot Max Efficiency DH5α-T1 E. coli according to the
manufacturer's suggested protocol (Invitrogen). Competent E. coli cells were transformed by heat shock and
plated on agarose plates containing ampicillin and S-gal
(Sigma). White colonies were checked for DNA inserts by
PCR with vector specific M13 primers performed directly
on the colonies according to the manufacturer's protocol
(Invitrogen) and visualized on ethidium-bromide stained
1% agarose gels. Positive colonies were amplified and
plasmids purified with Qiagen's Miniprep Kit. The target
DNA inserts were identified by DNA sequencing using
vector specific M13 primers.
Separation of cytosolic and nuclear proteins
Nuclear and cytoplasmic proteins were isolated by a protocol adapted from Panomics, Inc. for their Nuclear
Extrcation Kit. Nuclear protein concentration was determined by BCA assay (Pierce), aliquoted and either used
immediately to prepare samples for SDS-PAGE or stored
at -70°C. Oligonucleotides corresponding to the β-casein
gene promoter for STAT5 (5'-AGA TTT CTA GGA ATT CAA
TCC-3') and NFκB consensus binding site (5'-AGT TGA
GGG GAC TTT CCC AGG C-3') were obtained from Santa
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Cruz Biotechnology, Inc. and labeled with T4 Polynucleotide Kinase and [γ-32P]-ATP followed by ethanol precipitation. The nuclear extract/DNA binding mixtures were
resolved on 5% native PAGE, dried and exposed to X-ray
film.

Inc., polyclonal anti-Ser536-p65 antibody from Cell Signaling, Inc. and all antibodies used at a dilution recommended by the manufacturer. Western blots were detected
by enhanced chemiluminescence (ECL). For all samples,
total protein was determined by the BCA method (Pierce).

Electromobility Shift Assay and cold competition assay
EMSA was performed as described previously [41,42]. To
validate the results of ChIP-cloning, randomly selected
clones were amplified by PCR using vector specific M13
primers and the products isolated by the Qiagen PCR
Purification Kit. DNA integrity was assessed using 1% agarose gel. The amplified inserts were used as cold competitors at 30–50-fold molar access in EMSA reactions using 5
μg IL-2-stimulated YT nuclear extracts and a [32P]-radiolabeled STAT5 DNA binding probe. As a positive control,
cold competition was also performed with an amplified
known STAT5 binding site located 5' to the human CISH
gene (Forward: 5'-CTA TTG GCC CTC CCC GAC CG-3'
Reverse: 5'-GGC GAG CTG CTG CCT AAT CC-3') [18] or
IL2RA gene (primer sequences indicated above). The
results were quantitated by Scion Image (Scion Corporation) or Un-Scan-It gel Version 6.1 (Silk Scientific Corporation) densitometry analysis software. Supershift
analysis was performed with polyclonal anti-p65 and
anti-p50 NFκB antibodies from Santa Cruz Biotechnology, Inc. by incubating the nuclear extract for 1 h at 4°C
prior to the binding reactions.

RNA isolation, cDNA synthesis and qRT-PCR
Total RNA was isolated from approximately 4–5 × 106
cells using the RNeasy kit (Qiagen), then DNase treated
and quantitated by measuring OD at 260 nm; cDNA was
synthesized with BioRad's iScript cDNA Synthesis Kit as
recommended by the manufacturer (0.5 μg total RNA/
each sample). Quantification based on real-time monitoring of amplification was determined using a BioRad iQ5
machine and 2× SYBR Green Mastermix (Biorad) with
primers for human BCL10 (NM_003921) as follows: Forward: 5'-CCCGCTCCGCCTCCTCTCCTT-3', Reverse: 5'GGCGCTTCTTCCGGGTCCG-3'. Relative numbers of
mRNA molecules were normalized to 18S rRNA to correct
for RNA concentration differences. Samples (cDNA corresponding to 5 ng total RNA/well) were run in triplicates in
25 μl reaction volumes with one control reaction containing no RT enzyme to test for potential DNA contamination. Values of transcripts in unknown samples were
obtained by interpolating Ct (PCR cycles to threshold)
values on a standard curve. Standard curves were prepared
from serial dilution of non-treated Kit225 cDNA, with 10fold differences, starting with cDNA corresponding to
62.5 ng total RNA/well to 6.25 pg total RNA/well. To
ensure that fluorescent signals were specifically generated,
a melting curve was obtained as recommended by BioRad.

In silico Analyses
To determine the localization of the ChIP-cloned fragments, plasmids from the positive colonies were isolated
and the inserts sequenced and located within the human
genome by using the UCSC web-tool BLAT at http://
genome.ucsc.edu/cgi-bin/hgBlat and Sanger Institute's
Ensemble genome browser at http://www.ensembl.org/
index.html. Proximal gene mapping of the genomic
sequences up to 300 kb was performed using the Cis-Regulatory Element Annotation System (CEAS) at http://
ceas.cbi.pku.edu.cn/index.html.
Viability (MTS) assay
Cell viability was assessed with MTS reagent (Promega) in
triplicates according to the manufacturer's instructions.
Three independent experiments were performed. The
error bars represent the standard deviation.
Cell lysis and Western blotting
Cell lysis and Western blots with antibodies to JAK3,
STAT5A or STAT5B were performed as previously
described [42]. Monoclonal anti-phosphotyrosine STAT5
and anti-BCL10 antibodies were obtained from Millipore,
monoclonal anti-STAT5 antibody from BD Biosciences,
monoclonal anti-GAPDH antibody from RDI, monoclonal anti-Lamin A/C and polyclonal anti-p65 and antip50 NFκB antibodies from Santa Cruz Biotechnology,

Plasmids and mutants
Expression plasmids for wild type and Y694F mutant
mouse STAT5A were kindly provided by Dr. Hallgeir Rui
and described in [27]. FLAG tagged versions of the cDNAs
were subsequently created using pCMV-Tag2B vector
(Stratagene), Hind III and Xho I cloning enzymes (NEB),
Pfu Ultra High Fidelity DNA Polymerase (Stratagene) and
T4 DNA Ligase (NEB). DNA amplification and purification steps were performed with Qiagen's Plasmid isolation and Purification Kits. All steps were carried out
according to the manufacturers' recommendations. YT
cells (2.5 million) were electroporated with an AMAXA
Nucleofector® and Cell Line Nucleofector® Kit T, using 2 μg
plasmid (1 μg pCMV-Tag2B and 1 μg pmaxGFP®) and program O-017, selected with 0.3 mg/ml G418 (Invitrogen)
and sorted with a Beckman Coulter Epics Altra Cell Sorter.
Statistical analyses
Normalized t-tests were performed using SigmaStat 3.1.

Abbreviations
AS: antisense; BCL10: B-cell leukemia/lymphoma 10;
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polymerase chain reaction; SIE: sis-inducible element;
STAT: Signal Transducer and Activator of Transcription.

Competing interests

http://www.molecular-cancer.com/content/8/1/67

7.

8.
9.

10.

The authors declare that they have no competing interests.
11.

Authors' contributions
ZSN designed, carried out experiments, interpreted and
analyzed the results and wrote the manuscript, MJL participated in the ChIP experiments, JR assisted with the draft
of the manuscript, AM generated the Y699F mutant of
mSTAT5B-pCMVTag2B, HR participated in the design of
the project and RAK designed the project and critically
revised the manuscript. All authors read and approved the
final manuscript.

12.

13.
14.
15.

Acknowledgements
This work was supported by a grant from the Lizanell and Colbert Coldwell
Foundation (to R.A.K.), a pilot project grant to Z.S.N. (NIGMS SCORE program, grant S06 GM008012-37) and made possible by Grant
5G12RR008124 from the National Center for Research Resources, a component of the National Institutes of Health. Z.S.N. was supported by the
Ken Purvis Training Award.
The Kit225 cells were a kind gift of Dr. James Johnston (Queens University,
Belfast, UK). The authors would like to thank Drs. Renato Aguilera and
Armando Valera (Border Biomedical Research Center Cell Culture and
High Throughput Screening Core Facility, UTEP, El Paso, TX) for their
assistance with cell sorting, Drs. James Karras (ISIS Pharmaceuticals,
Carlsbad, CA) and Stanislaw Stepkowski (The University of Toledo,
Toledo, OH) for providing antisense and control oligonucleotides and Dr.
Balint L. Balint (University of Debrecen, Medical and Health Science Center,
Debrecen, Hungary) for helpful discussions. NC1153 was generously provided by Dr. Jonathan Dimmock and synthesized by Drs. U. Das and A. Jha
(The University of Saskatchewan, Saskatoon, Saskatchewan, Canada).

16.

17.
18.
19.

20.

21.
22.

References
1.
2.
3.
4.
5.
6.

Nagy ZS, Ross J, Cheng H, Stepkowski SM, Kirken RA: Regulation
of lymphoid cell apoptosis by Jaks and Stats. Crit Rev Immunol
2004, 24:87-110.
Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
Lim CP, Cao X: Structure, function, and regulation of STAT
proteins. Mol Biosyst 2006, 2:536-550.
Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy
DE, Beug H, Freissmuth M, Sexl V: STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006, 10:77-87.
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG,
Albanese C, Darnell JE Jr: Stat3 as an oncogene. Cell 1999,
98:295-303.
Hoover RR, Gerlach MJ, Koh EY, Daley GQ: Cooperative and
redundant effects of STAT5 and Ras signaling in BCR/ABL
transformed hematopoietic cells.
Oncogene 2001,
20:5826-5835.

23.
24.

25.

26.

27.

Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F,
Fernandez-Luna JL: Blockade of the Bcr-Abl kinase activity
induces apoptosis of chronic myelogenous leukemia cells by
suppressing signal transducer and activator of transcription
5-dependent expression of Bcl-xL.
J Exp Med 2000,
191:977-984.
Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN: Stat5 activation is
uniquely associated with cytokine signaling in peripheral T
cells. Immunity 1999, 11:225-230.
Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D,
Hoffmeyer A, van Deursen J, Sangster MY, Bunting KD, Grosveld GC,
Ihle JN: Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999, 10:249-259.
Groner B, Hennighausen L: Linear and cooperative signaling:
roles for Stat proteins in the regulation of cell survival and
apoptosis in the mammary epithelium. Breast Cancer Res 2000,
2:149-153.
Humphreys RC, Hennighausen L: Signal transducer and activator
of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 1999, 10:685-694.
Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H,
Nevalainen MT: Inhibition of transcription factor Stat5 induces
cell death of human prostate cancer cells. J Biol Chem 2003,
278:27287-27292.
Orlando V: Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-chromatin immunoprecipitation. Trends
Biochem Sci 2000, 25:99-104.
Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ: Use of
chromatin immunoprecipitation to clone novel E2F target
promoters. Mol Cell Biol 2001, 21:6820-6832.
Weinmann AS, Yan PS, Oberley MJ, Huang TH, Farnham PJ: Isolating
human transcription factor targets by coupling chromatin
immunoprecipitation and CpG island microarray analysis.
Genes Dev 2002, 16:235-244.
Martone R, Euskirchen G, Bertone P, Hartman S, Royce TE, Luscombe NM, Rinn JL, Nelson FK, Miller P, Gerstein M, Weissman S,
Snyder M: Distribution of NF-kappaB-binding sites across
human chromosome 22.
Proc Natl Acad Sci USA 2003,
100:12247-12252.
Nelson EA, Walker SR, Alvarez JV, Frank DA: Isolation of unique
STAT5 targets by chromatin immunoprecipitation-based
gene identification. J Biol Chem 2004, 279:54724-54730.
LeBaron MJ, Xie J, Rui H: Evaluation of genome-wide chromatin
library of Stat5 binding sites in human breast cancer. Mol Cancer 2005, 4:6.
Kim HP, Kelly J, Leonard WJ: The basis for IL-2-induced IL-2
receptor alpha chain gene regulation: importance of two
widely separated IL-2 response elements. Immunity 2001,
15:159-172.
Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S,
Millar DG, Bouchard D, Wakeham A, Ohashi PS, Mak TW: Bcl10 is
a positive regulator of antigen receptor-induced activation
of NF-kappaB and neural tube closure. Cell 2001, 104:33-42.
Thome M: CARMA1, BCL-10 and MALT1 in lymphocyte
development and activation. Nat Rev Immunol 2004, 4:348-359.
Shen HM, Tergaonkar V: NFkappaB signaling in carcinogenesis
and as a potential molecular target for cancer therapy. Apoptosis 2009, 14:348-363.
Davie JR, Candido EP: Acetylated histone H4 is preferentially
associated with template-active chromatin. Proc Natl Acad Sci
USA 1978, 75:3574-3577.
Chatterjee-Kishore M, Wright KL, Ting JP, Stark GR: How Stat1
mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the
LMP2 gene. Embo J 2000, 19:4111-4122.
Cui X, Zhang L, Luo J, Rajasekaran A, Hazra S, Cacalano N, Dubinett
SM: Unphosphorylated STAT6 contributes to constitutive
cyclooxygenase-2 expression in human non-small cell lung
cancer. Oncogene 2007, 26:4253-4260.
Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger
K, Levy DE, Stark GR: Novel roles of unphosphorylated STAT3
in oncogenesis and transcriptional regulation. Cancer Res
2005, 65:939-947.
Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin
RA, Harmon JM, Hennighausen L, Kirken RA, Rui H: Role of serine

Page 15 of 16
(page number not for citation purposes)

Molecular Cancer 2009, 8:67

28.
29.

30.
31.
32.

33.

34.

35.
36.
37.

38.

39.

40.
41.

42.

http://www.molecular-cancer.com/content/8/1/67

phosphorylation of Stat5a in prolactin-stimulated betacasein gene expression. Mol Cell Endocrinol 2001, 183:151-163.
Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O: Signaling through the hematopoietic cytokine receptors. Annu
Rev Immunol 1995, 13:369-398.
Stepkowski SM, Kao J, Wang ME, Tejpal N, Podder H, Furian L, Dimmock J, Jha A, Das U, Kahan BD, Kirken RA: The Mannich base
NC1153 promotes long-term allograft survival and spares
the recipient from multiple toxicities. J Immunol 2005,
175:4236-4246.
Yang J, Stark GR: Roles of unphosphorylated STATs in signaling. Cell Res 2008, 18:443-451.
Chen LF, Greene WC: Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004, 5:392-401.
Behbod F, Nagy ZS, Stepkowski SM, Karras J, Johnson CR, Jarvis WD,
Kirken RA: Specific inhibition of Stat5a/b promotes apoptosis
of IL-2-responsive primary and tumor-derived lymphoid
cells. J Immunol 2003, 171:3919-3927.
Nagy ZS, Rui H, Stepkowski SM, Karras J, Kirken RA: A Preferential
Role for STAT5, not Constitutively Active STAT3, in Promoting Survival of a Human Lymphoid Tumor. J Immunol
2006, 177:5032-5040.
Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M, et al.: TCGF (IL 2)-receptor
inducing factor(s). I. Regulation of IL 2 receptor on a natural
killer-like cell line (YT cells). J Immunol 1985, 134:1623-1630.
Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP,
Guccion JG: Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 1980, 55:409-417.
Miyoshi I, Kubonishi I, Yoshimoto S, Shiraishi Y: A T-cell line
derived from normal human cord leukocytes by co-culturing
with human leukemic T-cells. Gann 1981, 72:978-981.
Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S,
Kita K, Uchino H: Establishment of an interleukin 2-dependent
human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell
leukemia/lymphoma virus. Blood 1987, 70:1069-1072.
Nagy ZS, Wang Y, Erwin-Cohen RA, Aradi J, Monia B, Wang LH, Stepkowski SM, Rui H, Kirken RA: Interleukin-2 family cytokines
stimulate phosphorylation of the Pro-Ser-Pro motif of Stat5
transcription factors in human T cells: resistance to suppression of multiple serine kinase pathways. J Leukoc Biol 2002,
72:819-828.
Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H: Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b
in prolactin-sensitive cells. J Biol Chem 1998, 273:30218-30224.
Oberley MJ, Tsao J, Yau P, Farnham PJ: High-throughput screening of chromatin immunoprecipitates using CpG-island
microarrays. Methods Enzymol 2004, 376:315-334.
Wilson KC, Finbloom DS: Interferon gamma rapidly induces in
human monocytes a DNA-binding factor that recognizes the
gamma response region within the promoter of the gene for
the high-affinity Fc gamma receptor. Proc Natl Acad Sci USA
1992, 89:11964-11968.
Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, Wang L, Pericle
F, Farrar WL: Tyrphostin AG-490 inhibits cytokine-mediated
JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 1999,
65:891-899.

Publish with Bio Med Central and every
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical researc h in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours — you keep the copyright

BioMedcentral

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

Page 16 of 16
(page number not for citation purposes)

